Expert Panel Consensus for Optimizing Outcomes in Neovascular Age-Related Macular Degeneration in the Context of Suboptimal Response to a Biosimilar: The Role of Aflibercept
Nirodhini Narendran, Clare Bailey, Louise Downey, Richard Gale, Ajay Kotagiri, Ian Pearce, Christina A Rennie, Sobha Sivaprasad, James Talks, Peter Morgan-Warren, Jackie Napier, Carolyn O’Neil, Timothy Seeborne · 2024
Read Expert Panel Consensus for Optimizing Outcomes in Neovascular Age-Related Macular Degeneration in the Context of Suboptimal Response to a Biosimilar: The Role of Aflibercept by Nirodhini Narendran, Clare Bailey, Louise Downey, Richard Gale, Ajay Kotagiri, Ian Pearce, Christina A Rennie, Sobha Sivaprasad, James Talks, Peter Morgan-Warren, Jackie Napier, Carolyn O’Neil, Timothy Seeborne (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11541223.txt.
Description
PurposeThe inclusion of ranibizumab biosimilars into National Health Service England commissioning recommendations published in 2022 created a need for expert guidance to optimize treatment outcomes in patients with neovascular age-related macular degeneration (nAMD) who otherwise may not have received first-line ranibizumab.
Catalog record
| CREATOR | Nirodhini Narendran, Clare Bailey, Louise Downey, Richard Gale, Ajay Kotagiri, Ian Pearce, Christina A Rennie, Sobha Sivaprasad, James Talks, Peter Morgan-Warren, Jackie Napier, Carolyn O’Neil, Timothy Seeborne |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |